823. Factor IX Expression in Skeletal Muscle of a Subject With Severe Hemophilia B Ten Years After AAV Gene Transfer

Molecular Therapy - United States
doi 10.1016/s1525-0016(16)37396-8
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

Elsevier BV

Related search

AAV-mediated Gene Transfer for Hemophilia

Genetics in Medicine
MedicineGenetics
2002English

Role of the Vector Genome and Underlying Factor IX Mutation in Immune Responses to AAV Gene Therapy for Hemophilia B

Journal of Translational Medicine
BiochemistryMedicineGeneticsMolecular Biology
2014English

Pharmacological Modulation of Humoral Immunity in a Nonhuman Primate Model of AAV Gene Transfer for Hemophilia B

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Major Role of Local Immune Responses in Antibody Formation to Factor IX in AAV Gene Transfer

Gene Therapy
Molecular MedicineGeneticsMolecular Biology
2005English

652. Long-Term Follow-Up of Hemophilia a Dogs for 2-7 Years Demonstrates Sustained Factor VIII Expression After AAV-Mediated Delivery

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2012English

Expression and Characterization of Gly-317 Variants of Factor IX Causing Variable Bleeding in Hemophilia B Patients

Biochemistry
Biochemistry
2015English

28. Intravenous Administration of Lentiviral Vectors Expressing Hyperactive Factor IX Converts Severe Into Mild Hemophilia B in a Canine Model

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2015English

Severe Hemophilia B

2020English

Engineered Factor VII, Factor IX, and Factor X Variants for Hemophilia Gene Therapy

Journal of Genetic Syndromes & Gene Therapy
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy